TransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Rating of "Moderate Buy" from Analysts

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) has received a consensus rating of "Moderate Buy" from the eleven brokerages that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $126.70.

Several research analysts recently issued reports on TMDX shares. Canaccord Genuity Group reiterated a "buy" rating and set a $104.00 price target on shares of TransMedics Group in a research report on Tuesday, March 11th. Oppenheimer upped their target price on shares of TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a research report on Friday, May 9th. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research report on Wednesday, April 23rd. Finally, Piper Sandler reissued an "overweight" rating and set a $125.00 price target (up from $105.00) on shares of TransMedics Group in a research note on Friday, May 9th.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX traded up $0.09 during trading on Friday, reaching $128.62. The stock had a trading volume of 598,706 shares, compared to its average volume of 1,357,511. The stock has a market capitalization of $4.35 billion, a PE ratio of 136.83 and a beta of 1.91. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. TransMedics Group has a 52 week low of $55.00 and a 52 week high of $177.37. The business's 50-day moving average price is $93.03 and its 200 day moving average price is $78.14.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.41. The firm had revenue of $143.54 million during the quarter, compared to the consensus estimate of $123.39 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business's revenue for the quarter was up 48.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.35 EPS. As a group, equities analysts predict that TransMedics Group will post 1 earnings per share for the current year.

Insider Buying and Selling at TransMedics Group

In other news, Director David Weill sold 732 shares of TransMedics Group stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $123.88, for a total transaction of $90,680.16. Following the transaction, the director now owns 12,134 shares in the company, valued at $1,503,159.92. The trade was a 5.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Edward M. Basile sold 6,000 shares of the firm's stock in a transaction that occurred on Friday, May 9th. The stock was sold at an average price of $115.63, for a total transaction of $693,780.00. Following the sale, the director now owns 732 shares in the company, valued at $84,641.16. This trade represents a 89.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.00% of the company's stock.

Institutional Investors Weigh In On TransMedics Group

Several large investors have recently made changes to their positions in the stock. Clear Creek Financial Management LLC acquired a new position in TransMedics Group in the 4th quarter worth $352,000. Vaughan Nelson Investment Management L.P. lifted its holdings in shares of TransMedics Group by 9.9% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company's stock valued at $22,547,000 after purchasing an additional 32,605 shares in the last quarter. Baillie Gifford & Co. boosted its position in shares of TransMedics Group by 14.9% during the fourth quarter. Baillie Gifford & Co. now owns 269,836 shares of the company's stock worth $16,824,000 after buying an additional 34,947 shares during the period. State of Michigan Retirement System bought a new position in shares of TransMedics Group during the 4th quarter worth approximately $6,734,000. Finally, Peregrine Capital Management LLC boosted its holdings in TransMedics Group by 64.0% during the fourth quarter. Peregrine Capital Management LLC now owns 66,140 shares of the company's stock worth $4,124,000 after purchasing an additional 25,814 shares during the last quarter. Institutional investors own 99.67% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.